ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Quantitative assessment of tumor burden in multiple myeloma using MY-RADS from whole-body MRI: comparison with established prognostic biomarkers.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the value of MY-RADS from whole-body MRI in assessing tumor burden in MM with reference to established prognostic biomarkers.
methods108 consecutive newly diagnosed MM patients were retrospectively enrolled. Bone marrow (BM) infiltration patterns were determined by MRI presentation. The whole-body total burden score using MY-RADS, apparent diffusion coefficient (ADC), and fat fraction (FF) of representative background BM were measured. Spearman correlation analysis was used for correlating these parameters against plasma cell infiltration ratio, and independent sample t-test was used to evaluate the differences between different International Staging System (ISS) and free light-chain ratio groups.
resultsFor diffuse, salt-and-pepper and normal patterns, patients with advanced ISS stage and high FLC-ratio had markedly lower FF and higher ADC of representative background BM. They also correlated well with plasma cell infiltration ratio. In contrast, the total burden score did not show significant difference between groups. For focal pattern, there was no significant difference of ADC and FF between groups. They didn't correlate with plasma cell infiltration ratio as well. While, patients with advanced ISS stage and high FLC-ratio had markedly higher MY-RADS total burden score and correlated well with plasma cell infiltration ratio. For mixed pattern, ADC for L3, FF for L3 and the total burden score all showed statistical difference and correlated well with plasma cell infiltration ratio.
conclusionThe present study supports the applicability of MY-RADS as a surrogate biomarker when established prognostic biomarkers were not accessible conveniently.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.